版本:
中国

BRIEF-BioLineRX says topline results for phase 2 BL-8040 study expected by 2017-end

March 20 BioLineRx Ltd:

* BioLineRx provides update on phase 2 open-label study for BL-8040 as novel stem cell mobilization treatment

* Top-Line results expected by end of 2017

* BL-8040 treatment was safe and well tolerated

* All recipients transplanted so far have experienced a successful neutrophil engraftment Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐